NASDAQ:BDTX Black Diamond Therapeutics Q4 2025 Earnings Results & Report $1.44 -0.09 (-5.88%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$1.46 +0.02 (+1.04%) As of 11/17/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Black Diamond Therapeutics beat analyst earnings expectations in its Q4 2025 results, released March 16, 2026. The company reported EPS of -$0.14 versus the -$0.18 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 16, 2026TimeBefore Market OpensConference Call7:00 AM ET Black Diamond Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$0.18Beat/MissBeat by +$0.04One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersBlack Diamond Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$9.38 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Black Diamond Therapeutics Q4 2025 Earnings FAQ Did Black Diamond Therapeutics beat earnings estimates for Q4 2025? Black Diamond Therapeutics (NASDAQ:BDTX) reported earnings of -$0.14 per share for Q4 2025, beating the consensus estimate of -$0.18. The report was announced on Monday, March 16, 2026. Black Diamond Therapeutics Earnings HeadlinesBlack Diamond Posts Strong Silevertinib Data; FDA Supports Phase 3 Path; Shares RiseNovember 10, 2026 | rttnews.comBlack Diamond Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10, 2026 | marketscreener.comMYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills. | Profits Run (Ad)Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and ...November 10, 2026 | finance.yahoo.comBlack Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate UpdateNovember 10, 2026 | globenewswire.comBlack Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in ...November 9, 2026 | finance.yahoo.comSee More Black Diamond Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Black Diamond Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Diamond Therapeutics and other key companies, straight to your email. Email Address About Black Diamond TherapeuticsBlack Diamond Therapeutics (NASDAQ:BDTX) is a clinical-stage biotechnology company focused on developing precision medicines for people with genetically defined cancers. The company uses its discovery platform to identify cancer-causing mutations and develop small-molecule therapies designed to target them. Its pipeline has included BDTX-1535, an investigational inhibitor designed to target certain EGFR alterations in cancers such as non-small cell lung cancer. The company’s candidates are in clinical development; it does not have an approved commercial product. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics conducts research and clinical development with the goal of addressing cancer mutations that may not be served by existing treatments.View Black Diamond Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.